{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:35:59Z","timestamp":1791005759225,"version":"4.1.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Endothelin receptor antagonists (ERAs), including bosentan, ambrisentan, and macitentan, are recognized as first-line treatments for pulmonary arterial hypertension (PAH). Although their therapeutic efficacy is well established, variations in receptor selectivity and metabolic pathways may lead to distinct adverse drug event (ADE) profiles. Nonetheless, large-scale, real-world comparative safety data remain limited. As part of routine pharmacovigilance activities, we analyzed data from the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS) to identify disproportionate reporting signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study leveraged data from FAERS to identify and compare potential ADEs associated with bosentan, ambrisentan, and macitentan, thereby facilitating safer and more informed clinical decision-making in pharmacotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A disproportionality analysis of individual case safety reports (ICSRs) from the FAERS was performed for the period spanning Q1 2004 to Q2 2025. The classification of ADEs was conducted utilizing the Medical Dictionary for Regulatory Activities (MedDRA\u00ae) terminology. Signal detection was executed employing four distinct algorithms: the Reporting Odds Ratio (ROR), the Proportional Reporting Ratio (PRR), the Bayesian Confidence Propagation Neural Network (BCPNN), and the Multi-item Gamma Poisson Shrinker (MGPS), all based on an observational and retrospective proportional imbalance analysis of the FAERS database. Additionally, a Time-to-Onset (TTO) analysis was conducted to evaluate the temporal distribution of ADEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 35,112, 48,411, and 29,877 ADE reports were collected for bosentan, ambrisentan, and macitentan, respectively. The majority of reports originated from female patients, with a male-to-female ratio of 1:2.91, aged between 18 and 65 years. Ambrisentan was disproportionally more frequently reported the highest incidence of ADEs, accounting for 42.69% of cases. Significant ADE signals were identified in the hepatobiliary, hematologic, cardiovascular, respiratory, and fluid retention-related categories. The observed ADEs predominantly comprised peripheral edema, dyspnea, liver function abnormalities, and anemia, consistent with the documented drug labeling. It is crucial that novel signals were identified, including jaw pain, pulmonary thrombosis, gout, decreased blood potassium, and hypotension. TTO analysis revealed that the majority of ADEs occurred within the first year of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study corroborated the established ADEs associated with ERAs and identified novel ADE signals, thereby providing new insights into their safety profile. The findings emphasize the importance of comprehensive monitoring of hepatic function, blood pressure, renal function, and electrolyte levels during ERA treatment. These results provide valuable insights for clinicians aiming to optimize ERA utilization, minimize associated risks, and improve patient outcomes. Future research should focus on elucidating the underlying mechanisms of these ADEs to further enhance the safety and efficacy of ERA therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1712783","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:31:20Z","timestamp":1773120680000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Disproportionality analysis of adverse events associated with endothelin receptor antagonists based on the FDA adverse event reporting system (FAERS)"],"prefix":"10.3389","volume":"13","author":[{"given":"Lizhu","family":"Han","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianting","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinan","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changli","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Bian","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/jama.2022.4402","article-title":"Diagnosis and treatment of pulmonary arterial hypertension: a review","volume":"327","author":"Ruopp","year":"2022","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1093\/eurheartj\/ehn234","article-title":"Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?","volume":"29","author":"Opitz","year":"2008","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1161\/HYPERTENSIONAHA.119.12105","article-title":"Endothelin: 30 years from discovery to therapy","volume":"74","author":"Barton","year":"2019","journal-title":"Hypertension"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1161\/01.CIR.92.11.3312","article-title":"Endothelin at pathophysiological concentrations mediates coronary vasoconstriction via the endothelin-A receptor","volume":"92","author":"Cannan","year":"1995","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrcardio.2017.84","article-title":"Epidemiology and treatment of pulmonary arterial hypertension","volume":"14","author":"Lau","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1161\/01.CIR.89.3.1203","article-title":"Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels","volume":"89","author":"Seo","year":"1994","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s40264-015-0275-y","article-title":"Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension","volume":"38","author":"Aversa","year":"2015","journal-title":"Drug Saf"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1002\/phar.2078","article-title":"Serious liver injury associated with macitentan: a case report","volume":"38","author":"Tran","year":"2018","journal-title":"Pharmacotherapy"},{"key":"B10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40199-020-00386-1","article-title":"Bosentan-induced immune hemolytic anemia in 17 years old man. A case report","volume":"29","author":"Afra","year":"2021","journal-title":"Daru"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1323057","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"Cutroneo","year":"2023","journal-title":"Front Drug Saf Regul"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1111\/bcp.15802","article-title":"Considerations on the use of different comparators in pharmacovigilance: a methodological review","volume":"89","author":"Gravel","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B14","doi-asserted-by":"publisher","first-page":"D51","DOI":"10.1016\/j.jacc.2013.10.023","article-title":"Pulmonary arterial hypertension: epidemiology and registries","volume":"62","author":"McGoon","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"115681","DOI":"10.1016\/j.ejmech.2023.115681","article-title":"Development of novel bosentan analogues as endothelin receptor antagonists for pulmonary arterial hypertension","volume":"259","author":"Panchal","year":"2023","journal-title":"Eur J Med Chem"},{"key":"B16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.recesp.2016.01.002","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"69","author":"Gali\u00e8","year":"2016","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.lfs.2012.02.003","article-title":"Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice","volume":"91","author":"Ling","year":"2012","journal-title":"Life Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1345\/aph.1C256","article-title":"Bosentan for the treatment of pulmonary arterial hypertension","volume":"37","author":"Kenyon","year":"2003","journal-title":"Ann Pharmacother"},{"key":"B19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40262-015-0255-5","article-title":"Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan","volume":"54","author":"Sidharta","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1517\/17425255.2011.557181","article-title":"Pharmacokinetic evaluation of ambrisentan","volume":"7","author":"Buckley","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S0168-8278(02)00107-1","article-title":"Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan","volume":"37","author":"Fouassier","year":"2002","journal-title":"J Hepatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1067\/mcp.2001.114667","article-title":"The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions","volume":"69","author":"Fattinger","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e87548","DOI":"10.1371\/journal.pone.0087548","article-title":"Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes","volume":"9","author":"Lepist","year":"2014","journal-title":"PLoS One"},{"key":"B24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2147\/dddt.s3786","article-title":"Safety and tolerability of bosentan in the management of pulmonary arterial hypertension","volume":"3","author":"Roberts","year":"2009","journal-title":"Drug Des Devel Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2165\/00003088-200443150-00003","article-title":"Clinical pharmacology of bosentan, a dual endothelin receptor antagonist","volume":"43","author":"Dingemanse","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40265-013-0156-6","article-title":"Macitentan: first global approval","volume":"74","author":"Patel","year":"2014","journal-title":"Drugs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/1753465812458014","article-title":"An update on the use of ambrisentan in pulmonary arterial hypertension","volume":"6","author":"D'Alto","year":"2012","journal-title":"Ther Adv Respir Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1161\/hc0902.105719","article-title":"Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension","volume":"105","author":"Bauer","year":"2002","journal-title":"Circulation"},{"key":"B29","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1124\/jpet.116.234930","article-title":"Endothelin ET(A) receptor blockade, by activating ET(B) receptors, increases vascular permeability and induces exaggerated fluid retention","volume":"361","author":"Vercauteren","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e14059","DOI":"10.1111\/eci.14059","article-title":"Long-term safety of macitentan in patients with pulmonary hypertension: a meta-analysis of randomised controlled trials","volume":"53","author":"Wang","year":"2023","journal-title":"Eur J Clin Invest"},{"key":"B31","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1701886","DOI":"10.1183\/13993003.01886-2017","article-title":"Macitentan in pulmonary hypertension due to left ventricular dysfunction","volume":"51","author":"Vachi\u00e9ry","year":"2018","journal-title":"Eur Respir J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1517\/14796678.1.3.299","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"1","author":"Provencher","year":"2002","journal-title":"Future Cardiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1164\/rccm.200410-1411OC","article-title":"Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study","volume":"171","author":"Wilkins","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial","volume":"371","author":"Gali\u00e8","year":"2008","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1161\/01.CIR.102.4.411","article-title":"Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension","volume":"102","author":"Williamson","year":"2000","journal-title":"Circulation"},{"key":"B37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1161\/01.CIR.0000105701.98663.D4","article-title":"Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice","volume":"109","author":"Yang","year":"2004","journal-title":"Circulation"},{"key":"B38","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1681\/ASN.2006030208","article-title":"Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism","volume":"18","author":"Sasser","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1161\/01.CIR.0000144462.08345.B9","article-title":"Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction","volume":"110","author":"Amiri","year":"2004","journal-title":"Circulation"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1161\/01.CIR.0000094397.19932.78","article-title":"Endothelin receptor blockers in cardiovascular disease","volume":"108","author":"Rich","year":"2003","journal-title":"Circulation"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.jacc.2006.01.057","article-title":"Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan","volume":"47","author":"Barst","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":"Ambrisentan therapy for pulmonary arterial hypertension","volume":"46","author":"Gali\u00e9","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.healun.2016.04.013","article-title":"Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: the VOLibris tracking study","volume":"36","author":"Vachi\u00e9ry","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"B44","doi-asserted-by":"publisher","first-page":"591","DOI":"10.5603\/CJ.a2014.0072","article-title":"Neuropeptides and peptide hormones in syncope and orthostatic intolerance","volume":"21","author":"Krishnan","year":"2014","journal-title":"Cardiol J"},{"key":"B45","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/joim.12043","article-title":"Novel cardiovascular biomarkers in unexplained syncopal attacks: the SYSTEMA cohort","volume":"273","author":"Fedorowski","year":"2013","journal-title":"J Intern Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1161\/hy0302.105222","article-title":"Effect of endothelin blockade on basal and stimulated forearm blood flow in patients with essential hypertension","volume":"39","author":"Martin","year":"2002","journal-title":"Hypertension"},{"key":"B47","doi-asserted-by":"publisher","first-page":"450s","DOI":"10.1042\/CS103S450S","article-title":"Roles of angiogenic factors and endothelin-1 in gastric ulcer healing","volume":"103","author":"Akimoto","year":"2002","journal-title":"Clin Sci (Lond)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1161\/01.RES.70.5.1027","article-title":"Effect of endothelin on plasma volume and albumin escape","volume":"70","author":"Zimmerman","year":"1992","journal-title":"Circ Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"691","DOI":"10.12669\/pjms.35.3.84","article-title":"Changes of serum IGF-1 and ET-1 levels in patients with osteoporosis and its clinical significance","volume":"35","author":"Sun","year":"2019","journal-title":"Pak J Med Sci"},{"key":"B50","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1042\/CS20240341","article-title":"Endothelin-1 impairs skeletal muscle myogenesis and development via ETB receptors and p38 MAPK signaling pathway","volume":"138","author":"Liu","year":"2024","journal-title":"Clin Sci (Lond)"},{"key":"B51","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1358863X9700200106","article-title":"The endothelin system in cardiovascular physiology and pathophysiology","volume":"2","author":"Parris","year":"1997","journal-title":"Vasc Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1161\/CIRCULATIONAHA.110.967406","article-title":"Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis","volume":"122","author":"Reriani","year":"2010","journal-title":"Circulation"},{"key":"B53","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: bREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"key":"B54","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.lfs.2012.03.026","article-title":"Endothelin and endothelin receptors in the renal and cardiovascular systems","volume":"91","author":"Vignon-Zellweger","year":"2012","journal-title":"Life Sci"},{"key":"B55","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/cvr\/cvac027","article-title":"Aldosterone and cardiovascular diseases","volume":"119","author":"Parksook","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B56","article-title":"TEVA-BOSENTAN\u2019s PRODUCT MONOGRAPH","year":"2012"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s40264-025-01624-8","article-title":"Charting and sidestepping the pitfalls of disproportionality analysis","volume":"48","author":"Fusaroli","year":"2025","journal-title":"Drug Saf"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1712783\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:31:21Z","timestamp":1773120681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1712783\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":57,"alternative-id":["10.3389\/fcvm.2026.1712783"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1712783","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"article-number":"1712783"}}